

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

INSIDE INFORMATION: RECEIPT OF CIVIL RULING

This announcement is made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Cap 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Unless otherwise specified, capitalised terms used in this announcement has the same meanings as those defined in the inside information announcement of the Company dated 26 December 2017 (“**December Announcement**”).

1. BACKGROUND

In the December Announcement, it was disclosed, among other things, that pursuant to the Arbitration Ruling, Golden Force was ordered to transfer 98,378,439 shares in Wang Lao Ji to the Company. Then in 26 March 2018, the Company disclosed that it received an application for revocation of arbitration ruling submitted by Golden Force to the Shenzhen Peoples’ Intermediate Court* (深圳市中級人民法院).

2. CIVIL RULING

The Company announces that it received a civil ruling of Shenzhen Peoples’ Intermediate Court wherein application for the revocation of the Arbitration Ruling submitted by Golden Force has been rejected.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 11 June 2018

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.

* *For identification purpose only*